-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nowadays, it is a good time for spring to return to the earth and all things to recover, but many people suffer from "allergies"
The top three products dominate half of the country
Yangtze River Pharmaceutical ranks first
The top three products dominate half of the country
In terms of seasons of each year, the sales of antiallergic drugs have a certain seasonality, which also shows that in spring and autumn, due to the blooming of hundreds of flowers and the increase in the number of pollen, the number of allergic people and the number of medical treatment has increased
From the perspective of drugs, there will be 34 anti-allergic drugs sold in the sample hospitals in 2021, and the top three sales of desloratadine, dust mites, and ebastine will account for 50.
Yangtze River Pharmaceutical ranks first
From the perspective of enterprises, there are 181 manufacturers selling anti-allergic drugs in the sample hospitals in 2021, of which the sales of Yangzijiang Pharmaceutical Group (including 4 subsidiaries) accounted for 29.
TOP10 drugs account for 90% of the share
From the perspective of drugs, there are 32 anti-asthmatic drugs sold in the sample hospitals in 2021, including budesonide, budesonide + formoterol compound, terbutaline, montelukast and fluticasone + salmeterol compound Top four
Local companies still need to catch up
From the perspective of enterprises, there are 151 manufacturers selling anti-asthmatic drugs in the sample hospitals in 2021, of which the sales of AstraZeneca's two companies accounted for 41.
summary
In China, on the one hand, with the implementation of the previous batches of national centralized procurement, antiallergic drugs such as levocetirizine, desloratadine, cetirizine, loratadine, bepotastine, etc.
Drugs such as montelukast, albuterol, doxofylline, etc.
have also entered the centralized procurement, which has the effect of reducing the sales amount but increasing the amount of use, covering more patient groups and reducing the burden on patients and medical insurance; on the other hand , with the launch of more new drugs, such as anti-allergic drug Artemisia annua pollen allergen sublingual drops and targeted biological agents omalizumab, dupilimumab, etc.
have been launched and entered the country one after another, especially monoclonal antibodies The relatively high price will inevitably increase the sales amount in this field.
At the same time, it will be used as a new treatment method to meet clinical needs and provide more treatment options for different patients
.
